Phase 1 Lip Clinical Trials
54 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 54 trials
Recruiting
Phase 1
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Triple-Negative Breast CancerColorectal, CancerSarcoma+5 more
Valo Therapeutics Oy15 enrolled7 locationsNCT05492682
Recruiting
Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
Healthy ParticipantsDyslipidemia
AstraZeneca136 enrolled6 locationsNCT06980428
Recruiting
Phase 1
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Neuromyelitis Optica Spectrum Disorder (NMOSD)+6 more
Polina Stepensky120 enrolled1 locationNCT07085676
Recruiting
Phase 1Phase 2
Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride
Lipoma
West Virginia University20 enrolled1 locationNCT06820164
Recruiting
Phase 1
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
HypercholesterolemiaHypertriglyceridemiaRefractory Hyperlipidemia
Verve Therapeutics, Inc.36 enrolled10 locationsNCT06451770
Recruiting
Phase 1Phase 2
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
SarcomaSolid TumorLeiomyosarcoma+1 more
STORM Therapeutics LTD107 enrolled6 locationsNCT06975293
Recruiting
Phase 1Phase 2
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled6 locationsNCT06239272
Recruiting
Phase 1
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Locally Advanced Head and Neck Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8+23 more
National Cancer Institute (NCI)46 enrolled18 locationsNCT05172245
Recruiting
Phase 1
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
Synovial SarcomaMyxoid/Round Cell Liposarcoma
M.D. Anderson Cancer Center44 enrolled1 locationNCT06083883
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Metastatic Soft Tissue SarcomaMetastatic LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more
National Cancer Institute (NCI)74 enrolled1 locationNCT06498648
Recruiting
Phase 1
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Metastatic SarcomaMetastatic LeiomyosarcomaUnresectable Leiomyosarcoma+9 more
National Cancer Institute (NCI)30 enrolled16 locationsNCT05711615
Recruiting
Phase 1Phase 2
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
OsteosarcomaEwing SarcomaNeuroblastoma+2 more
Milton S. Hershey Medical Center104 enrolled21 locationsNCT06541262
Recruiting
Phase 1
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 1
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Liver CancerRhabdomyosarcomaWilms Tumor+3 more
Baylor College of Medicine24 enrolled1 locationNCT04715191
Recruiting
Phase 1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
HypercholesterolaemiaMetabolic DiseaseDyslipidemias+7 more
CRISPR Therapeutics AG90 enrolled18 locationsNCT07491172
Recruiting
Phase 1Phase 2
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
LiposarcomaDedifferentiated LiposarcomaPleomorphic Liposarcoma+6 more
Memorial Sloan Kettering Cancer Center54 enrolled7 locationsNCT06843967
Recruiting
Phase 1
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Metastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+20 more
Emory University40 enrolled2 locationsNCT06868433
Recruiting
Phase 1
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting
Phase 1
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721